Weinhaeusel Andreas, Thiele Susanne, Hofner Manuela, Hiort Olaf, Noehammer Christa
Austrian Research Centers GmbH-ARC, Molecular Diagnostics, Seibersdorf, Austria.
Clin Chem. 2008 Sep;54(9):1537-45. doi: 10.1373/clinchem.2008.104216. Epub 2008 Jul 10.
Pseudohypoparathyroidism type Ib (PHPIb) is characterized by parathyroid hormone (PTH) resistance, which can lead to hypocalcemia, hyperphosphatemia, and increased serum PTH. The disorder is caused by mutations in regulatory regions of the GNAS gene (GNAS complex locus) that lead to interferences in the methylation status of alternative GNAS promoters, such as exon A/B, NESP55, and XL alpha-s. PHPIb comprises disorders that show distinctive changes in methylation status but share the same clinical phenotype: (a) loss of methylation only at exon A/B of the GNAS gene and involving no other obvious epigenetic abnormalities [e.g., those caused by heterozygous microdeletions in the STX16 (syntaxin 16) region and found in many patients with autosomal dominant (AD) PHPIb]; (b) methylation abnormalities at several differentially methylated regions (DMRs), which are observed in most patients with sporadic PHPIb and some families with AD PHPIb.
To permit early and reliable diagnosis of suspected PHPIb, we designed methylation-sensitive restriction enzyme-based and bisulfite deamination-based PCR tests for exon A/B and NESP55 DMRs.
Both PCR strategies permit proper methylation testing of GNAS and NESP55 DMRs and elucidate different disease subtypes. We have identified a novel microsatellite repeat polymorphism within GNAS exon A/B, and pedigree analyses have shown its presence to be conclusive evidence for familial disease.
We provide a simple diagnostic test for PHPIb, an imprinting disorder caused by different molecular changes within the GNAS complex locus. PHPIb, a complex and diagnostically challenging clinical phenotype, can be treated successfully by taking steps before the manifestation of symptoms to avoid clinical complications in affected patients or asymptomatic members of affected families who show positive results in genetic tests.
I b型假性甲状旁腺功能减退症(PHPIb)的特征是甲状旁腺激素(PTH)抵抗,可导致低钙血症、高磷血症和血清PTH升高。该疾病由GNAS基因(GNAS复合位点)调控区域的突变引起,这些突变会干扰替代性GNAS启动子(如外显子A/B、NESP55和XLα-s)的甲基化状态。PHPIb包括甲基化状态有明显变化但临床表型相同的疾病:(a)仅GNAS基因外显子A/B的甲基化缺失,且无其他明显的表观遗传异常[例如,由STX16( syntaxin 16)区域杂合微缺失引起的异常,见于许多常染色体显性(AD)PHPIb患者];(b)几个差异甲基化区域(DMR)的甲基化异常,见于大多数散发性PHPIb患者和一些AD PHPIb家族。
为了对疑似PHPIb进行早期可靠诊断,我们设计了基于甲基化敏感限制酶和亚硫酸氢盐脱氨基的PCR检测方法,用于检测外显子A/B和NESP55 DMR。
两种PCR策略都能对GNAS和NESP55 DMR进行适当的甲基化检测,并阐明不同的疾病亚型。我们在GNAS外显子A/B内发现了一种新的微卫星重复多态性,系谱分析表明其存在是家族性疾病的确凿证据。
我们为PHPIb提供了一种简单的诊断检测方法,PHPIb是一种由GNAS复合位点内不同分子变化引起的印记障碍。PHPIb是一种复杂且诊断具有挑战性的临床表型,通过在症状出现前采取措施,可以成功治疗,以避免受影响患者或在基因检测中呈阳性的受影响家族无症状成员出现临床并发症。